Xenetic Biosciences (XBIO) Cost of Revenue (2011 - 2017)

Xenetic Biosciences' (XBIO) quarterly Cost of Revenue came in at $97028.0 in Q3 2017, up 64.2% on a QoQ basis from $59091.0 in Q2 2017.

Xenetic Biosciences (XBIO) Cost of Revenue (2011 - 2017) Analysis & Trends

Xenetic Biosciences (XBIO) has 4 years of Cost of Revenue data on file, last reported at $97028.0 in Q3 2017.

Quarterly Cost of Revenue changed N/A year-over-year to $97028.0 in Q3 2017, while the trailing twelve-month figure through Sep 2018 was $156119.0 (changed 0.0% YoY) and the FY2013 annual result came in at $8435.0, down 69.07% from the prior year.
Cost of Revenue improved to $97028.0 in Q3 2017, from $59091.0 in the prior quarter.
In the past five years, Cost of Revenue ranged from a high of $97028.0 in Q3 2017 to a low of $3502.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	93.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	174.53 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	298.26 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	387.98 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	67.21 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Xenetic Biosciences	8.01 Mn	1.54 Mn	-	-

Download Data